isoniazid
| Product dosage: 300mg | |||
|---|---|---|---|
| Package (num) | Per pill | Price | Buy |
| 90 | $0.50 | $45.21 (0%) | 🛒 Add to cart |
| 120 | $0.46 | $60.28 $55.26 (8%) | 🛒 Add to cart |
| 180 | $0.42 | $90.42 $75.35 (17%) | 🛒 Add to cart |
| 270 | $0.39 | $135.63 $106.49 (21%) | 🛒 Add to cart |
| 360 | $0.38
Best per pill | $180.84 $136.63 (24%) | 🛒 Add to cart |
Synonyms
| |||
Isoniazid remains one of those foundational tuberculosis drugs that every clinician should understand deeply, not just from textbooks but from real patient experience. When I first started working in our TB clinic back in 2012, I’ll admit I viewed isoniazid as just another medication in our arsenal - until I saw what happened when we got the dosing wrong with Mrs. Gable, a 68-year-old with latent TB who developed peripheral neuropathy after we missed checking her B6 levels. That case taught me more about this drug than any pharmacology lecture ever did.
## 1. Introduction: What is Isoniazid? Its Role in Modern Medicine
Isoniazid, or INH as we usually call it in clinical practice, is a first-line antibacterial agent specifically used for tuberculosis treatment and prevention. What many don’t realize is that it’s actually a prodrug - it requires activation by bacterial catalase-peroxidase to become effective against Mycobacterium tuberculosis. We’ve been using this medication since the 1950s, and despite all the new drugs developed since then, it remains cornerstone therapy for both active TB disease and latent TB infection.
The significance of isoniazid in global TB control cannot be overstated - when used properly in appropriate regimens, it helps prevent transmission, reduces development of drug-resistant strains, and has contributed significantly to declining TB mortality rates worldwide. Though we now understand its limitations better than we did decades ago, particularly regarding hepatotoxicity risks and the need for pyridoxine supplementation in certain patients.
## 2. Key Components and Bioavailability of Isoniazid
The chemical structure is deceptively simple - isonicotinic acid hydrazide - but its pharmacokinetics are what make it both effective and challenging to use. We typically administer it orally, though parenteral forms exist for特殊情况.
Bioavailability is excellent - nearly 100% when taken on empty stomach, though we often recommend with food to reduce GI upset, which only slightly reduces absorption. Peak serum concentrations occur within 1-2 hours post-administration. The real challenge comes with its metabolism - primarily through N-acetyltransferase 2 (NAT2) in the liver, which leads to the fast versus slow acetylator phenomenon that affects dosing strategies and toxicity risks.
We’ve learned through hard experience that the acetylator status matters more than we initially thought. Fast acetylators may require higher doses for efficacy, while slow acetylators accumulate the drug and face increased hepatotoxicity risks. This genetic polymorphism varies by ethnicity - approximately 40-70% of Caucasians and African Americans are slow acetylators, while only 10-20% of Asians fall into this category.
## 3. Mechanism of Action of Isoniazid: Scientific Substantiation
The mechanism is fascinating - isoniazid inhibits mycolic acid synthesis, which are essential components of the mycobacterial cell wall. Think of it as undermining the structural integrity of the bacterial fortress. More specifically, it targets the enoyl-acyl carrier protein reductase (InhA), disrupting the fatty acid synthesis pathway unique to mycobacteria.
What’s particularly clever about this mechanism is the bacterial activation requirement - the drug must be activated by KatG (catalase-peroxidase) within the bacterium itself. This activation produces multiple reactive species that attack various bacterial targets, creating a multi-pronged assault that makes complete resistance development more challenging, though not impossible.
The bactericidal activity is concentration-dependent against rapidly dividing organisms, while it exhibits bacteriostatic activity against dormant bacilli. This dual activity explains why we use it in both active disease and prevention scenarios.
## 4. Indications for Use: What is Isoniazid Effective For?
Isoniazid for Active Tuberculosis Treatment
Always in combination therapy - never as monotherapy due to resistance concerns. We typically use it with rifampin, pyrazinamide, and ethambutol in the initial intensive phase, then continue with isoniazid and rifampin in the continuation phase. The duration depends on disease site and severity.
Isoniazid for Latent Tuberculosis Infection
This is where we’ve seen some of the biggest impacts in TB control. For patients with positive TB tests but no active disease, we use isoniazid monotherapy for 6-9 months. The 9-month regimen provides approximately 90% protection against progression to active disease when adherence is good.
Isoniazid for TB Prevention in Special Populations
HIV-positive individuals with latent TB benefit significantly from isoniazid preventive therapy, reducing TB incidence by 30-60%. We also use it for recent contacts of infectious TB cases and patients with radiographic evidence of prior TB who never received adequate treatment.
Isoniazid for Nontuberculous Mycobacteria
Limited role here - occasionally used for Mycobacterium kansasii infections in combination regimens, but generally not first-line for most NTM infections.
## 5. Instructions for Use: Dosage and Course of Administration
Dosing varies significantly based on indication and patient factors:
| Indication | Adult Dose | Frequency | Duration | Special Instructions |
|---|---|---|---|---|
| Active TB | 5 mg/kg (max 300 mg) | Daily | 6-9 months | Always combine with other TB drugs |
| Latent TB | 5 mg/kg (max 300 mg) | Daily | 9 months | Preferred regimen |
| Latent TB | 15 mg/kg (max 900 mg) | Twice weekly | 9 months | Directly observed therapy |
| Pediatric | 10-15 mg/kg (max 300 mg) | Daily | Varies | Weight-based dosing critical |
We typically recommend morning dosing, and while absorption is better on empty stomach, we often suggest taking with food if GI intolerance occurs. The slight reduction in bioavailability is usually clinically insignificant.
Monitoring requirements are non-negotiable - baseline liver function tests, then monthly symptom review with LFTs if symptoms develop. We check for hepatitis symptoms at every visit - nausea, vomiting, abdominal pain, jaundice, unexplained fatigue.
## 6. Contraindications and Drug Interactions of Isoniazid
Absolute contraindications include severe previous reaction to isoniazid, acute liver disease of any etiology, and severe peripheral neuropathy. Relative contraindications include chronic liver disease, alcoholism, and pregnancy - though we often use it in pregnancy when benefits outweigh risks.
The drug interactions are substantial and clinically important:
- Anticonvulsants: Increases phenytoin and carbamazepine levels significantly - requires monitoring and dose adjustment
- Benzodiazepines: May increase effects of triazolam and midazolam
- Acetaminophen: Increased risk of hepatotoxicity - we advise limiting to <2g/day
- Alcohol: Regular use increases hepatitis risk dramatically
- Tyramine-rich foods: May cause headache, flushing, palpitations due to MAO inhibition
- Antacids: Aluminum-containing antacids may decrease absorption
The peripheral neuropathy risk necessitates pyridoxine (vitamin B6) supplementation at 25-50 mg daily in high-risk groups: diabetics, alcoholics, HIV-positive, pregnant women, and patients with nutritional deficiencies.
## 7. Clinical Studies and Evidence Base for Isoniazid
The evidence supporting isoniazid use spans decades. The landmark USPHS trials in the 1950s-70s established its efficacy for both treatment and prevention. More recent studies have refined our understanding:
The PREVENT TB study demonstrated that 3 months of weekly rifapentine plus isoniazid was non-inferior to 9 months of daily isoniazid for latent TB, offering another effective option.
The TEMPRANO trial showed that isoniazid preventive therapy reduced severe HIV-related illness and death by 44% among HIV patients in Côte d’Ivoire, highlighting its importance in HIV/TB co-infection management.
Meta-analyses consistently show that 6-12 months of isoniazid for latent TB reduces active TB risk by 60-90%, with longer durations providing greater protection.
The concerning data comes from resistance patterns - primary isoniazid resistance rates have increased to approximately 8-10% globally, necessitating drug susceptibility testing whenever possible.
## 8. Comparing Isoniazid with Similar Products and Choosing Quality Medication
When comparing TB preventive regimens, we consider several factors:
- Isoniazid monotherapy (9 months): Gold standard efficacy but longer duration challenges adherence
- Rifapentine plus isoniazid (3 months): Shorter duration, weekly dosing, but higher pill burden per dose and more drug interactions
- Rifampin monotherapy (4 months): Good alternative for isoniazid-resistant strains or intolerance
For active TB treatment, isoniazid remains irreplaceable in first-line regimens when susceptibility is confirmed. The fixed-dose combinations like Rifater (isoniazid/rifampin/pyrazinamide) improve adherence but limit dosing flexibility.
Quality considerations include ensuring proper storage (protection from moisture and light), checking expiration dates, and using manufacturers with good manufacturing practice certification. We’ve seen variability in generic products, so consistency in supplier matters.
## 9. Frequently Asked Questions (FAQ) about Isoniazid
What monitoring is required during isoniazid therapy?
Baseline LFTs are essential, then clinical monitoring for hepatitis symptoms monthly. We only repeat LFTs if symptoms develop in asymptomatic patients. Regular assessment for peripheral neuropathy is also important.
How should missed doses be handled?
If a daily dose is missed, take it as soon as remembered unless it’s almost time for the next dose. Don’t double dose. For twice-weekly regimens under direct observation, reschedule within a few days if possible.
Can isoniazid be used during pregnancy?
Yes, when clearly needed. The benefits generally outweigh risks for both active TB treatment and latent TB in high-risk women. We always add pyridoxine and monitor more closely.
What should patients do if they develop yellow eyes or dark urine?
Stop isoniazid immediately and seek urgent medical attention - these are signs of possible hepatotoxicity requiring prompt evaluation.
How common is isoniazid resistance?
Primary resistance rates vary geographically but average 8-10% globally. We always consider resistance possibilities when treatment response is suboptimal.
## 10. Conclusion: Validity of Isoniazid Use in Clinical Practice
Despite being one of our older anti-TB drugs, isoniazid maintains its vital role in tuberculosis control when used appropriately with attention to its specific toxicities and monitoring requirements. The risk-benefit profile remains favorable for both treatment and prevention when guidelines are followed.
I remember when our team debated switching entirely to newer regimens for latent TB - the 3-month rifapentine/isoniazid regimen seemed so appealing with its shorter duration. But then I thought about Carlos, a construction worker with irregular hours who’d never manage the directly observed therapy required for the weekly regimen. The flexibility of daily isoniazid, despite the longer course, actually worked better for his life. Sometimes the older, more familiar option remains the right choice for the individual patient in front of you.
We’ve followed Maria, now 72, for eight years since completing her isoniazid preventive therapy after her husband was treated for pulmonary TB. She remains TB-free and still calls every Christmas to update us. “Still clean, doc!” she always says. These longitudinal relationships remind us why we put up with the monitoring challenges and occasional hepatotoxicity scares - because when isoniazid works, it prevents devastating illness and saves lives. The evidence base continues to support its central role, though we’ve learned to use it more wisely than our predecessors did.